20 Most Obese States in America in 2023

In This Article:

In this article, we are going to discuss the 20 most obese states in America in 2023. You can skip our detailed analysis of obesity in the U.S., the least obese state in America, the socioeconomic factors of obesity, new weight-loss drugs, innovations in the insulin industry, and the financial cost of obesity, and go directly to 5 Most Obese States in America in 2023

Obesity in the U.S.:

Obesity is a common, chronic disease among many U.S. adults and children. With America’s obesity rate of 38.2%, it is ranked among the Most Obese Countries in the World. Also, obesity is also one of the 15 biggest issues in America.

The National Institute of Health has suggested that if the current trends of obesity continue, the obesity rate in America in 2050 could be as high as 100%. 

Least Obese State in America:

With an adult obesity rate of 25%, Hawaii is the least obese state in 2023. The Aloha State has now beaten Colorado, where 25.1% of the adult population is classified as obese, according to the Centers for Disease Control and Prevention

Socioeconomic Factors of Obesity:

Obesity is negatively proportional to income level, with increased rates of obesity noted in low income populations. Individuals with limited financial means often live in food deserts and gravitate towards convenient stores and food sources that are highly processed, low in nutrient density, and high in caloric content with a long shelf life. The cost associated with fresh produce at these locations can be up to four times the cost of fresh produce purchased from grocery stores. 

New Weight-Loss Drugs:

Positive trial data showing that the obesity drug by Novo Nordisk A/S (NYSE:NVO) actually helps save and extend lives, and not just lose weight, could propel the Danish company’s stock even higher. Demand for Novo Nordisk A/S (NYSE:NVO)’s weight-loss treatment Wegovy is soaring in the U.S., leading the company to upgrade its operating profit growth expectations to between 28% and 34%, up from a February guidance of between 13% and 19%. 

Similarly, Eli Lilly and Company (NYSE:LLY) is also in the middle of phase three clinical trials of its weight-loss oral drug, Orforglipron, meaning it’s likely to hit the market later. Still, analysts are confident in the competitive edge of Orforglipron in the long-run, especially after Eli Lilly and Company (NYSE:LLY) unveiled its phase two clinical trial results in June, which showcased the drug’s strong efficacy profile. Eli Lilly and Company (NYSE:LLY) is one of the Biggest Diet/Weight Loss Companies in the World

Barclays estimates that the burgeoning weight-loss drug industry could be worth as much as $200 billion within the next decade, with most of the benefit accrued to early leaders, like Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Company (NYSE:LLY).